You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅本化學(300261.SZ):公司卡龍酸酐及其衍生產品的客户主要為國內客户及印度客户、預計A2W的CBD醫用產品將延期至2023年一季度實現正式投產
格隆匯 12-27 22:07

格隆匯12月27日丨雅本化學(300261.SZ)發佈股票交易異常波動公吿,公司關注到近期互動易平台投資者對於公司卡龍酸酐及其衍生產品的關注度較高,針對相關情況作出如下澄清及風險提示:截止至本公吿披露日,公司未與輝瑞公司(Pfizer)簽署任何合作協議,與其不存在任何合作關係,未向輝瑞公司供應卡龍酸酐及其衍生產品。公司卡龍酸酐及其衍生產品的客户主要為國內客户及印度客户,無法確定公司卡龍酸酐及其衍生產品是否間接供給輝瑞公司。公司卡龍酸酐及其衍生產品本年度銷售收入佔公司本年度營業總收入的比例約為0.5%-2%,佔比較小,不會對公司業績產生重大影響。敬請投資者注意投資風險,審慎決策,理性投資。

公司關注到近期互動易平台投資者對於公司CBD醫用產品的關注度較高,針對相關情況作出如下澄清及風險提示:截止至本公吿披露日,公司馬耳他子公司A2W Pharma Ltd. (“A2W”)的CBD(大麻二酚)醫用產品生產車間主體結構已基本建成,目前正在進行設備安裝及申請GMP認證,本年度未生產和銷售任何CBD醫用產品。受歐洲疫情影響,公司預計A2W的CBD醫用產品將延期至2023年一季度實現正式投產,2021年度和2022年度將不會為公司帶來任何銷售收入和利潤貢獻。另,A2W的GMP認證過程具有不確定性,可能影響CBD醫用產品的投產進度。敬請投資者注意投資風險,審慎決策,理性投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account